Emergent BioSolutions has acquired Cangene bioPharma. Emergent BioSolutions is a global specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Emergent's mission is simple - to protect and enhance life. Emergent BioSolutions contract manufacturing site (previously known as Cangene bioPharma) provides fill/finish services to pharmaceutical and biotechnology companies from its Baltimore, Maryland manufacturing plant. The contract manufacturing plant aseptically fills liquid and lyophilized products in vials and syringes. The site currently produces 24 commercial products and since 1990 has contributed to the development and production of more than 185 clinical products. Emergent BioSolutions’ fill/finish manufacturing plant has been inspected and approved by regulatory agencies in the US, EU, Brazil, Middle East and Japan. Products manufactured for clients are distributed to over 50 countries worldwide.